Betadex Sulfobutyl Ether Sodium Salt CAS No.: 182410-00-0

Description:
Zhiyuan Betadex Sulfobutyl Ether Sodium Salt is an anionic bcyclodextrin
derivative with a sodium sulfonate salt separated from the hydrophobic
cavity by a butyl spacer group. The substituent is introduced at positions
2, 3, and 6 in at least one of the glucopyranose units in the cyclodextrin
structure. Introducing the sulfobutylether (SBE) into beta cyclodextrin can
produce materials with different degrees of substitution, theoretically from
1 to 21; the hepta-substituted preparation (SBE7-b-CD) is the cyclodextrin
with the most desirable drug carrier properties. Betadex Sulfobutyl Ether
Sodium Salt China occurs as a white amorphous powder.
Betadex Sulfobutyl Ether Sodium salt is an excipient mainly used in
nitrogen-containing drugs. It has special affinity and inclusion properties
for nitrogen-containing drugs.
Characteristics & Applications:
Betadex Sulfobutyl Ether Sodium Salt is a chemically modified cyclodextrin
with a structure designed to optimize the solubility and stability of
drugs.The amount of Betadex Sulfobutyl Ether Sodium Salt that may be used is
dependent on the purpose for inclusion in the formulation, the route of
administration, and the ability of the cyclodextrin to complex with the drug
being delivered.
Pharm Grade Betadex Sulfobutyl Ether Sodium salt is the sulfonated modified
sodium salt of beta cyclodextrin,which is an anionic, highly water-soluble
cyclodextrin derivative, can be well incorporated with drug molecules to
form non-covalent complexes, thereby improving the stability, water
solubility and safety of the drug , reducing nephrotoxicity, ease drug
hemolysis, control drug release rate, mask bad odor, etc.
Betadex Sulfobutyl Ether Sodium Salt is derived from beta cyclodextrin,
which is nephrotoxic when administered parenterally. However, studies have
shown that Betadex Sulfobutyl Ether Sodium Salt is well tolerated at high
doses, when administered via intravenous bolus injections, orally, and by
inhalation. Up to 9 g/day may be administered by IV infusion in a licensed
voriconazole formulation. The safety following high doses of Betadex
Sulfobutyl Ether Sodium Salt intravenous administration in humans is
continually being investigated.
Zhiyuan Betadex Sulfobutyl Ether Sodium Salt has been subjected to an
extensive battery of in vitro and in vivo genotoxicity and pharmacological
evaluations. No genotoxic or mutagenic changes were observed with Betadex
Sulfobutyl Ether Sodium Salt administration. Betadex Sulfobutyl Ether Sodium
Salt is biocompatible and exhibits no pharmacological activity. It is
rapidly eliminated unmetabolized when administered intravenously.

Click to Enlarge